Daiichi Sankyo ( Daiichi Sankyo)

Primary tabs

Daiichi Sankyo's picture

Management

Contact Address

About Daiichi Sankyo

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 50 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients. Through the outstanding knowledge and commitment of our 30,000 employees worldwide, we create innovative new and generic medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.

Daiichi Sankyo press release, blog etc

Tue, 03/30/2021 - 19:54 Ratio of Share Contribution
Fri, 08/07/2020 - 02:27 Daiichi Sankyo Selected as Provider for Japanese Governments Emergent Initiative to Build Production Capacity for COVID-19 Vaccines (First Round)
Tue, 07/21/2020 - 01:09 Daiichi Sankyo Announces Phase 3 Study Results for Prasugrel Antiplatelet Agent in Thrombotic Stroke Patients
Fri, 07/10/2020 - 01:53 Daiichi Sankyo Announces Participation in AMR Action Fund
Mon, 06/29/2020 - 02:16 Daiichi Sankyo Provides Update on CHMP Review of Pexidartinib, a CSF1R Inhibitor for the Treatment of Patients with TGCT
Fri, 06/26/2020 - 02:59 Daiichi Sankyo Announces Start of Discussions with AstraZeneca Regarding Supply in Japan of Novel Corona Virus Vaccine
Mon, 06/08/2020 - 01:32 The University of Tokyo, RIKEN, Nichi-Iko and Daiichi Sankyo Reach Basic Agreement on Collaborative R&D on Nafamostat Inhalation Formulation for Treatment of Novel Corona Virus Infection (COVID-19)
Mon, 05/18/2020 - 02:40 ENHERTU Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Mon, 05/11/2020 - 04:27 Daiichi Sankyo Announces Changes to Representative Directors and Members of the Board
Mon, 05/11/2020 - 03:28 ENHERTU Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric Cancer
Sun, 04/26/2020 - 22:42 Daiichi Sankyo Announces Removal of Contaminated Soil Storage Facility from Site of Former Yasugawa Plant in Japan
Tue, 04/14/2020 - 01:45 Daiichi Sankyo Contributes to Relief Efforts for Countermeasures against COVID-19
Mon, 04/13/2020 - 01:58 Daiichi Sankyo, Mitsubishi UFJ Capital and Nagoya Institute of Technology Announce Open Innovation Research on Gene Therapy to Restore Vision
Wed, 04/01/2020 - 13:18 Daiichi Sankyo Enters into Strategic Partnership with Ultragenyx for Use of Gene Therapy Manufacturing Technology
Mon, 03/30/2020 - 02:21 Daiichi Sankyo Submits Application for CAR T Therapy Axicabtagene Ciloleucel for Treatment of Patients with Certain Relapsed/Refractory B-cell Lymphomas in Japan
Fri, 03/27/2020 - 11:37 Daiichi Sankyo and Kitasato Pharmaceutical Industry to End Sales Cooperation for Influenza HA Vaccine Daiichi Sankyo in Japan
Wed, 03/25/2020 - 07:55 ENHERTU Approved in Japan for Treatment of Patients with HER2 Positive Unresectable or Metastatic Breast Cancer
Thu, 02/27/2020 - 04:01 Anti-epilepsy Drug VIMPAT , Submission for Supplemental Application for Approval in Japan